Philips CPAP Health Lawsuit: Recall, MDL, and $1.1B Settlement

The Philips CPAP lawsuit settlement refers to more than $1.5 billion that Philips Respironics has agreed to pay across two separate deals tied to its 2021 recall of roughly 15 million sleep and breathing machines: a resolved economic loss settlement that paid more than $500 million to people who owned or paid for a recalled device, and a $1.1 billion fund covering personal injury, wrongful death, and medical monitoring claims. The economic loss claim window closed on August 9, 2024, and personal injury registration closed on January 31, 2025, so most eligibility doors are already shut, with a narrow set of options still open in 2026.

What the Recall Covered

In June 2021, Philips recalled CPAP, BiPAP, and mechanical ventilator devices manufactured between 2009 and April 2021 because the polyester-based polyurethane (PE-PUR) foam used to dampen sound could degrade into particles or release volatile organic compounds. Users could inhale or swallow that material while the machine ran. The recall covered popular models including the DreamStation, SystemOne, Dorma, and Trilogy ventilator lines, with about 10.8 million units sold in the United States.¹ By 2024, the FDA had received more than 116,000 medical device reports connected to the recall, including at least 561 reports of death.²

The lawsuits were consolidated as MDL No. 3014 before Senior U.S. District Judge Joy Flowers Conti in the Western District of Pennsylvania.³ Philips has consistently denied that its devices caused the reported injuries.⁴

The Economic Loss Settlement

The first settlement was about money spent on the machines, not health injuries. In September 2023, Philips agreed to pay at least $479 million to resolve claims from people, entities, and insurers who had purchased, leased, been prescribed, or reimbursed the cost of a recalled device. The fund ultimately delivered more than $500 million to class members.⁴²

The money was split into buckets: at least $445 million for device payment and return awards, up to $15 million for device replacement awards, and $34 million for third-party payers such as insurers. Individual payouts varied by model, running from about $55.63 for a DreamStation CPAP up to $1,552.25 for a Trilogy 100/200 ventilator, plus an extra $100 for returning a recalled device.⁵ Around 3 million class members registered and 1.6 million returned their machines.²

Judge Conti granted final approval on April 25, 2024. The claim filing deadline was August 9, 2024, and the settlement did not cover personal injury or medical monitoring claims.⁵³ That window is closed.

The $1.1 Billion Personal Injury and Medical Monitoring Settlement

On April 29, 2024, Philips reached a separate $1.1 billion settlement covering personal injury, wrongful death, and medical monitoring claims. Of that total, $1.075 billion funds the personal injury and wrongful death claims and $25 million funds medical monitoring.⁴ The Master Settlement Agreement was executed on May 9, 2024, and Philips was scheduled to deposit $1.05 billion into a Qualified Settlement Fund by March 14, 2025.⁶

Unlike the economic loss deal, this one is not a class action. Each claim is evaluated individually under an Allocation Methodology published on July 23, 2024. Qualifying injuries include new-onset asthma, COPD, and pulmonary fibrosis, along with cancers of the lung, thyroid, oropharynx, and esophagus, among others. Base awards require an injury diagnosed on or before April 29, 2024.⁷

How Payouts Are Calculated

Claimants who registered were asked to choose between two tracks:⁷

The Expedited Payout Program pays a fixed amount with simpler paperwork and faster processing.
The Fixed Evaluation Program uses a point system running from 25 to 2,750 points. Claimants who reach at least Severity Level 1 get a minimum of $4,000 before deductions. The point track is designed for people with more serious injuries or multiple qualifying conditions.

Average per-case payouts are estimated at $25,000 to $35,000, depending on whether 30,000 or 40,000 claimants qualify. Attorneys involved in the litigation have estimated that individual cancer claims could reach $100,000 to $500,000, though those figures turn on severity and individual facts.⁴

The Extraordinary Injury Fund

Between $75 million and $150 million is carved out of the settlement as an Extraordinary Injury Fund (EIF) for situations the standard formula does not fully capture: death from a qualifying injury, surgeries or extended hospitalizations tied to qualifying cancers, permanent impairment, and injuries first diagnosed after the April 29, 2024 cutoff.⁷ The EIF methodology and application materials were posted on February 20, 2025, and applications were due by August 1, 2025. Decisions by the Allocation Special Master are final and not subject to appeal, though a claimant can request reconsideration within 30 days.⁸

What Medical Monitoring Actually Provides

The $25 million medical monitoring piece was set up as a mandatory, non-opt-out class under Federal Rule 23(b)(2) that covers every U.S. resident who used a recalled device. It does not pay for individual doctor visits or screenings. Instead, it funds a “Medical Advancement Program” with three parts: independent medical research into detecting and treating qualifying injuries, a research registry for class members to share medical data, and an interactive website with health guidance about long-term effects. The benefits are designed to run for 15 years.⁹ A preliminary approval hearing was scheduled for June 18, 2024.³

Deadlines and What Remains Open

The main claim windows for the two settlements are closed:

Economic loss claim filings closed August 9, 2024.⁵
Personal injury registration closed January 31, 2025, with a final medical records supplementation deadline of February 20, 2025.⁷
EIF applications were due August 1, 2025.⁸

As of early 2026, the economic loss settlement is fully resolved and funds have been distributed. The personal injury fund is in its payout phase, with smaller claims being processed and paid first. Lien resolution, the process of reimbursing health insurers before plaintiffs get their share, is the main factor slowing disbursements.⁸² A handful of opt-out cases remain pending but face significant procedural hurdles and are widely expected to be dismissed.

Cases Filed Outside the MDL

Not every claim has to sit inside the federal MDL. In January 2026, Judge Conti denied Philips’ attempt to keep a cancer-related CPAP lawsuit centralized in Pennsylvania and remanded it to Kentucky state court. The plaintiff, a Kentucky woman who alleged a recalled sleep apnea machine caused her cancer, had also named a local supplier as a defendant. The court found the claims against the supplier viable under Kentucky law, which defeated the federal diversity jurisdiction Philips relied on to keep the case in the MDL.¹⁰ The ruling could give some plaintiffs a template for litigating closer to home rather than joining the MDL.

Objections Raised During Approval

The economic loss deal drew only 78 objections, and no objectors appeared at the fairness hearing.³⁸

What the Science Says About Cancer Risk

Whether PE-PUR foam exposure actually causes cancer is not scientifically settled, and this drives much of Philips’ defense. A 2022 study in Laryngoscope analyzed the FDA’s adverse-event database and found 209 cancer reports linked to CPAP devices, with 95.7% filed in 2021 after the recall. Of 1,902 foam-degradation reports in the database, 174 were associated with a cancer diagnosis. The authors cautioned that the spike could reflect a “bandwagon effect” following the recall rather than a true causal link and called for more research.¹¹

A systematic review Philips published in July 2022 examined 13 epidemiological studies and concluded no association had been established between PAP device use and cancer risk. Two larger studies, from Ontario and France, each followed thousands of patients for more than seven years and found no statistically significant difference in cancer rates between Philips users and users of other brands.¹² In October 2023, the FDA determined that Philips’ testing and analysis were not sufficient to fully evaluate the risks and ordered additional testing, which remains underway.¹³

A separate FDA consent decree entered on April 9, 2024 by U.S. District Judge Robert J. Colville bars Philips from selling new CPAP or BiPAP machines in the United States until it satisfies compliance conditions; the company can only service existing devices and sell accessories.¹⁴¹⁵ That order governs Philips’ ability to return to market and is separate from the claimant settlement funds; it does not affect what individual users can recover.

1
U.S. Food and Drug Administration. Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines
2
Seeger Weiss LLP. Philips CPAP Recall Litigation
3
U.S. District Court for the Western District of Pennsylvania. MDL 3014 Case Page
4
Drugwatch. Philips CPAP Lawsuits
5
Respironics CPAP-EL Settlement. Economic Loss Settlement FAQs
6
Respironics PI Settlement. Philips Respironics Personal Injury Settlement Program
7
Respironics PI Settlement. PI Settlement FAQs
8
Lawsuit Information Center. CPAP Sleep Apnea MDL
9
ClassAction.org. Philips CPAP Medical Monitoring Settlement Terms
10
The Legal Intelligencer. Federal Judge Sends Philips CPAP Suit to Kentucky State Court
11
National Center for Biotechnology Information. Cancer Risk Associated With Continuous Positive Airway Pressure: A National Study
12
Philips. PAP and Cancer Literature Review Summary
13
U.S. Food and Drug Administration. Foam Testing Summary for Recalled Philips Devices
14
U.S. Department of Justice. Court Enjoins Philips Respironics From Manufacturing and Distributing Adulterated and Misbranded Devices
15
Philips. Explained: Philips Respironics Consent Decree